0001267813false00012678132024-10-022024-10-02

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported): October 2, 2024

​

Marinus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

 

001-36576

 

20-0198082

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

​

, Radnor, PA

​

​

​

​

5 Radnor Corporate Center, Suite 500

100 Matsonford Rd, Radnor, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

​

Registrant’s telephone number, including area code: (484) 801-4670

​

__________________________________________________________________
(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

​

​

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

​

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

​

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

​

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001

MRNS

Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

​

​

Item 8.01. Other Events.

​

As previously disclosed, on March 26, 2024, Ovid Therapeutics, Inc. (“Ovid”) filed a petition (the “Petition”) with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (the “PTAB”) seeking Inter Partes Review (“IPR”) of one of the patents of Marinus Pharmaceuticals, Inc, (the “Company”) for the use of ganaxolone in treating status epilepticus (U.S. Patent No. 11,110,100). The Company filed a preliminary response to Ovid’s petition on June 26, 2024.

​

On September 20, 2024, the PTAB issued a decision denying institution of the IPR, stating that Ovid has not established a reasonable likelihood that it would prevail in showing the unpatentability of at least one claim challenged in the Petition. The decision is publicly available on the U.S. Patent Office’s website (uspto.gov). Ovid could choose to file for rehearing or seek director review at the PTAB within 30 days from the September 20, 2024 PTAB decision date. Ovid cannot appeal the denial of institution to the U.S. Court of Appeals for the Federal Circuit.

​

​

​

​

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

MARINUS PHARMACEUTICALS, INC.

​

​

Date: October 2, 2024

/s/ Steven Pfanstiel

​

Steven Pfanstiel

​

Chief Operating Officer, Chief Financial Officer and Treasurer

​

​

​

​

v3.24.3
Document and Entity Information
Oct. 02, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Oct. 02, 2024
Entity File Number 001-36576
Entity Registrant Name Marinus Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-0198082
Entity Address State Or Province PA
Entity Address, Address Line One 5 Radnor Corporate Center
Entity Address, Adress Line Two Suite 500
Entity Address, Address Line Three 100 Matsonford Rd
Entity Address, City or Town Radnor
Entity Address, Postal Zip Code 19087
City Area Code 484
Local Phone Number 801-4670
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol MRNS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001267813
Amendment Flag false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Marinus Pharmaceuticals
Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Marinus Pharmaceuticals